Cellectricon settles patent infringement litigation with Fluxion

Cellectricon AB and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in 2009.

Cellectricon and Fluxion have agreed to file a stipulation of dismissal with the United States District Court for the Northern District of California for all claims brought by Cellectricon against Fluxion for alleged infringement of Cellectricon's U.S. Patent Nos. 7,390,650, 7,470,518, and 7,563,614. Under the terms of the settlement, Fluxion and Cellectricon will cross-license patents related to microfluidic cellular analysis.

"We are very pleased to have achieved a successful conclusion to the litigation," said David A. Burns, Chief Executive Officer of Cellectricon. "Resolution of this lawsuit allows us to focus on providing innovative and enabling products and discovery services for drug discovery and life science research globally."

"Fluxion couldn't be more pleased with the settlement and the outcome of the litigation. We believe it is a win-win for both companies, and will benefit our customers as we can now focus all of our attention on developing and providing solutions that continue to deliver maximum benefit to them," said Jeff Jensen, CEO of Fluxion Biosciences.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Fluxion Biosciences. (2019, June 19). Cellectricon settles patent infringement litigation with Fluxion. News-Medical. Retrieved on April 21, 2024 from https://www.news-medical.net/news/20121015/Cellectricon-settles-patent-infringement-litigation-with-Fluxion.aspx.

  • MLA

    Fluxion Biosciences. "Cellectricon settles patent infringement litigation with Fluxion". News-Medical. 21 April 2024. <https://www.news-medical.net/news/20121015/Cellectricon-settles-patent-infringement-litigation-with-Fluxion.aspx>.

  • Chicago

    Fluxion Biosciences. "Cellectricon settles patent infringement litigation with Fluxion". News-Medical. https://www.news-medical.net/news/20121015/Cellectricon-settles-patent-infringement-litigation-with-Fluxion.aspx. (accessed April 21, 2024).

  • Harvard

    Fluxion Biosciences. 2019. Cellectricon settles patent infringement litigation with Fluxion. News-Medical, viewed 21 April 2024, https://www.news-medical.net/news/20121015/Cellectricon-settles-patent-infringement-litigation-with-Fluxion.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cellectricon resumes litigation against Fluxion Biosciences over alleged patent infringement